MAPT and Alzheimer disease: A recent pioglitazone-related study found that it may be of therapeutic benefit, showing a significant reduction in Aβ and tau pathology measured in cerebral blood flow from patients with early-stage and mild to moderate AD patients (Pérez and Quintanilla, 2015).